TD Cowen Has Lowered Expectations for BioNTech (NASDAQ:BNTX) Stock Price

Key Points

• TD Cowen cut its price target on BioNTech to $94 (from $116) and kept a “hold” rating, implying only about 3.2% upside from the current price.
• Negative catalysts — including the planned departure of co‑founders Ugur Sahin and Özlem Türeci and a reduced FY2026 revenue guide (~€2.0–2.3B) — triggered sharp intraday share declines and raised governance and legal concerns.
• Despite near‑term risks, BioNTech has a strong liquidity position (about €17.2B in cash/securities) and analysts still show a consensus of “Moderate Buy” with an average target of $132.43.

BioNTech (NASDAQ:BNTX - Get Free Report) had its price objective cut by analysts at TD Cowen from $116.00 to $94.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage currently has a "hold" rating on the stock. TD Cowen's price target points to a potential upside of 3.18% from the stock's current price.

A number of other research analysts have also recently weighed in on BNTX. Truist Financial set a $155.00 price objective on shares of BioNTech in a report on Tuesday. BMO Capital Markets reduced their target price on shares of BioNTech from $143.00 to $128.00 and set an "outperform" rating on the stock in a report on Wednesday. Morgan Stanley restated an "overweight" rating on shares of BioNTech in a research note on Tuesday. HC Wainwright reaffirmed a "buy" rating and set a $140.00 price objective on shares of BioNTech in a research report on Thursday, December 11th. Finally, Leerink Partners cut BioNTech from an "outperform" rating to a "market perform" rating and set a $113.00 price objective on the stock. in a research note on Monday, February 2nd. Eleven investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, BioNTech currently has an average rating of "Moderate Buy" and an average target price of $132.43.

BioNTech Trading Up 8.6%

NASDAQ BNTX traded up $7.21 during trading on Wednesday, hitting $91.10. The stock had a trading volume of 2,515,282 shares, compared to its average volume of 1,126,428. The company has a quick ratio of 7.02, a current ratio of 7.12 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $20.51 billion, a PE ratio of -34.64 and a beta of 1.51. The firm has a 50 day moving average price of $106.73 and a 200 day moving average price of $102.83. BioNTech has a twelve month low of $79.52 and a twelve month high of $124.00.

Institutional Investors Weigh In On BioNTech

Large investors have recently modified their holdings of the company. Royal Bank of Canada raised its holdings in shares of BioNTech by 95.9% in the 1st quarter. Royal Bank of Canada now owns 7,177 shares of the company's stock valued at $653,000 after purchasing an additional 3,514 shares in the last quarter. NewEdge Advisors LLC acquired a new position in shares of BioNTech during the first quarter worth $167,000. Envestnet Asset Management Inc. increased its holdings in BioNTech by 20.6% in the second quarter. Envestnet Asset Management Inc. now owns 10,570 shares of the company's stock valued at $1,125,000 after buying an additional 1,808 shares during the last quarter. Fox Run Management L.L.C. acquired a new stake in BioNTech in the second quarter valued at $303,000. Finally, Profund Advisors LLC raised its stake in BioNTech by 3.6% in the second quarter. Profund Advisors LLC now owns 4,309 shares of the company's stock valued at $459,000 after buying an additional 149 shares in the last quarter. 15.52% of the stock is owned by hedge funds and other institutional investors.

More BioNTech News

Here are the key news stories impacting BioNTech this week:

• Positive Sentiment: Strong balance sheet and pipeline: BioNTech reported €17.2B in cash and securities and outlined six late‑stage readouts and multiple oncology programs that management says derisk execution and support long‑term value creation. BioNTech corporate update and results
• Positive Sentiment: Potential upside from the co‑founders’ new venture: BioNTech will receive a minority stake in the new company and may earn milestone payments and royalties from contributed rights/technologies, creating optionality if next‑gen mRNA assets succeed. Co‑founders launch new mRNA venture
• Neutral Sentiment: Mixed quarter — EPS beat but revenue dynamics weak: BioNTech beat EPS estimates (reported ($0.39) vs. ($0.57) expected) and posted revenue of $1.06B (above consensus), but revenue is down ~24% YoY and adjusted losses were reported. Investors will parse beats vs underlying growth trends. Q4 2025 earnings highlights
• Neutral Sentiment: Analyst repositioning: Jefferies cut its price target (from $151 to $138) but kept a buy rating — signaling some analyst confidence on long‑term upside despite nearer‑term risks. Analyst PT change
• Negative Sentiment: Cofounders’ exit raises governance and execution concerns: Founders Ugur Sahin and Özlem Türeci will leave by end‑2026 to start a new company; BioNTech will transfer certain rights/tech, prompting investor worry about talent loss and strategic disruption. Reuters: founders to leave
• Negative Sentiment: Weaker FY2026 revenue guidance: Management cut 2026 revenue guidance to roughly €2.0–2.3B (below Street expectations), increasing near‑term growth concerns and pressuring sentiment. Full results and guidance
• Negative Sentiment: Regulatory/legal overhang: A plaintiff firm (Johnson Fistel) is investigating potential claims against BioNTech’s executives, adding legal risk and headline volatility. Johnson Fistel investigation notice
• Negative Sentiment: Immediate market reaction: Multiple outlets report a steep intraday share decline after the combined news of the founder exit and weaker outlook, reflecting selling pressure and short‑term sentiment deterioration. Market reaction coverage

About BioNTech

BioNTech SE NASDAQ: BNTX is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech's core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.